We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Parkinson's Disease Genome Study Data Made Available to Researchers

By Biotechdaily staff writers
Posted on 18 Mar 2008
Raw data obtained during the first genome-wide association study (GWAS) to focus on Parkinson's disease will become only the second dataset on Parkinson's disease to be made available through dbGaP, the database of Genotypes and Phenotypes operated by the [U.S.] National Library of Medicine's National Center for Biotechnology Information.

This first genome-wide association study applied to Parkinson's disease was funded under the Michael J. More...
Fox Foundation for Parkinson's Research (MJFF) Linked Efforts to Accelerate Parkinson's Solutions (LEAPS) initiative. Investigators at the Mayo Clinic (Rochester, MN, USA) in collaboration with colleagues at Perlegen Sciences, Inc. (Mountain View, CA, USA) carried out the study.

The [U.S.] National Human Genome Research Institute (NHGRI) and the [U.S.] National Center for Biotechnology Information (NCBI), both components of the [U.S.] National Institutes of Health (NIH), are sponsoring release of the GWAS data.

"Until now, the individual-level data from this study had been available only to a few researchers,” said Dr.Teri Manolio, director of the NHGRI Office of Population Genomics. "This is the first orphan data set NHGRI is adopting to make public through NCBI, but it certainly will not be the last. We appreciate the willingness of the LEAPS researchers and patients to share their data with the rest of the research community and hope it will increase our understanding of Parkinson's disease.”

"It's wonderful that NHGRI has agreed to facilitate access to this data by researchers around the globe working on Parkinson's disease,” said principal investigator Dr. Demetrius Maraganore, a neurologist at the Mayo Clinic. "Our hope is that these data will be used to make breakthroughs in the prevention and treatment of this devastating disease.”


Related Links:
Mayo Clinic
Perlegen Sciences
National Center for Biotechnology Information dbgap

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Rapid Flu Test
Influenza A&B Rapid Test Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.